CP Kelco Adds Four Non-GMO Project Verified Gellan Gums to Portfolio
ATLANTA, April 09, 2018 (GLOBE NEWSWIRE) -- CP Kelco, a leading global producer of specialty hydrocolloid solutions, announced today that four additional KELCOGEL® Gellan Gum products are Non-GMO Project (NGP) verified. NGP is a nonprofit organization dedicated to building and protecting a non-GMO food supply in North America.
Since the company's discovery of gellan gum, CP Kelco has evolved its product line to meet global market needs, including consumers' demand for non-GMO options. CP Kelco now offers 13 NGP-verified gellan gum products in its comprehensive portfolio:
KELCOGEL HA-B [E]
KELCOGEL LT 100 [E]
KELCOGEL LT 100-P [E]
KELCOGEL APL-B [E]
KELCOGEL APM-B [E]
KELCOGEL CG-HA [E]
KELCOGEL CG-LA [E]
KELCOGEL F [E]
KELCOGEL HF-B [E]
KELCOGEL HM-B [E]
KELCOGEL HM-PURE [E]
KELCOGEL HS-B [E]
These high-quality gellan gums provide protein protection, texture, gelling properties and particle suspension in a variety of applications, including but not limited to fruit juice beverages, alternative dairy beverages (i.e., soy, almond), flavored milks, acidified protein drinks, ambient yogurt drinks, sauces and personal care.
For the most up-to-date list of CP Kelco NGP verified products, visit the Non-GMO Project website. To learn more about these products and how to develop or improve formulations, send an email to email@example.com or visit http://www.cpkelco.com/.
About CP Kelco
Headquartered in Atlanta, Georgia, USA, and part of J.M. Huber Corporation, CP Kelco is a leading producer of specialty hydrocolloids with offices and facilities across the globe. Featuring an extensive range of hydrocolloid solutions and serving over 100 countries, CP Kelco leverages its capabilities to bring concepts and ideas to real-world products in a broad range of applications. The company's specialty ingredients touch a wide variety of consumer and household products and industrial applications, tailored to meet the needs of regional consumers. Key product lines are Gellan Gum, Pectin, Xanthan Gum, Cellulose Gum, Carrageenan, Diutan Gum and Microparticulated Whey Protein Concentrate, as well as other unique biopolymers. Visit http://www.cpkelco.com/ for more information.
Office: +1 678 247 7149
Mobile: +1 770 743 0564
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CP Kelco via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Inspiration in Receipt of Crypto Currency Proposal26.4.2018 16:54 | Pressemelding
TORONTO, April 26, 2018 (GLOBE NEWSWIRE) -- Inspiration Mining Corporation ("Inspiration" or the "Corporation") (CSE:ISM) is pleased to announce that it is contemplating upon the request of Compassion Cannabis that it is allowed to accept crypto currency for settlement for any transactions that occur. The logic is that it would make for easy settlement in any jurisdiction. The Company is not adverse to this proposal, but must perform its due diligence and will table the matter at the AGM. Compassion Cannabis is an Ontario Corp., which has expertise to forward various facets of the explosive new market of the marijuana industry, including but not limited to the "Vape" market and dispensary centers for the industry. We believe this will be an extremely lucrative space with tremendous demand in the medical cannabis industry. For further information, please contact Randy Miller, Chief Executive Officer of the Corporation, at tel: 416-842-9000, www.inspirationmining.com The CSE has not revi
SNOMED International Announces Brazil as its 33rd Member26.4.2018 15:12 | Pressemelding
London, United Kingdom, April 26, 2018 (GLOBE NEWSWIRE) -- Brazil's Ministry of Health and SNOMED International announce that as of April 1, 2018, Brazil has joined the organization as SNOMED International's thirty-third Member. With SNOMED CT already used in various parts of the country, Brazil joined SNOMED International to support nationwide health system transformation as a foundational element of its ehealth Strategy, digiSUS. As outlined in this national strategy, the SUS Monitoring and Evaluation Department of Brazil's Ministry of Health is responsible overall for governance of the National Electronic Health Strategy and its related evaluation and development. Demonstrated through its membership in SNOMED International, Brazil has defined SNOMED CT as the chosen international reference terminology for use in its clinical systems supporting the national ehealth strategy. SNOMED CT is the world's most comprehensive health terminology. Founded in 2007 by nine charter nations, SNOME
Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 201826.4.2018 14:30 | Pressemelding
Management to host conference call WALTHAM, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the first quarter of 2018 on Thursday, May 3, 2018. The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates. The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 8885379. A live webcast of the conference call will be available online in the Investors and Media section of the Company's website at ir.minervaneurosciences.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event for 30 days. About Minerva Neurosciences Mine
Talend Data Fabric Now Certified on MapR Converged Data Platform Version 6.026.4.2018 14:11 | Pressemelding
Latest Release of Talend's Data Integration Platform Enables Powerful New Use Cases in Data Privacy, Compliance Monitoring, Claims Processing, Retail Optimization, and More REDWOOD CITY, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- Talend (NASDAQ: TLND), a global leader in cloud and big data integration solutions, announced that the latest version of Talend Data Fabric is now certified for version 6.0 of the MapR Converged Data Platform, including MapR-DB and MapR-FS. The MapR Converged Data Platform is the industry's only enterprise-grade software solution that unifies big data and open source technologies with fast, native access to global event streaming, real-time database capabilities, and web-scale storage. Together, Talend and MapR provide a unified, open source-based data storage and management platform for an array of different applications, enabling organizations to harness big data in valuable ways to drive innovation and further their digital transformations. "Talend's powerf
CrownBio Launches New Humanized Target Model for Immunotherapy26.4.2018 14:00 | Pressemelding
SAN DIEGO, April 26, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, enhances its existing portfolio of humanized drug target models (HuGEMM(TM)) by launching a new transgenic CD3E model to advance development of immuno-oncology (I/O) drugs. Novel therapeutic T-cell redirecting antibodies, including bispecific T cell engagers, show great promise in effectively treating cancer. However, development of these drugs is hampered by a lack of in vivo models that can accurately recapitulate human specific responses. CrownBio addresses this need with their new CD3E transgenic model that was validated in collaboration with and developed by NBRI of Nanjing University. The CD3E model expresses the human form of CD3E and is phenotypically normal with levels
Jumio Achieves Record-Breaking Sales in Q1 2018, a 400% Increase Year-Over-Year26.4.2018 14:00 | Pressemelding
Spurred by growing traction in telecom, financial services and sharing economy, coupled with an increase in online fraud, Jumio announces best sales quarter to date PALO ALTO, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- Jumio Corporation, the leading AI-powered trusted identity as a service, today announced the best sales quarter in company history. Led by strong sales in telecom, financial services and the sharing economy, Jumio grew Q1 2018 sales of its Netverify® solution by more than 400 percent compared to the same quarter last year. This represents the second quarter out of the last three where the company increased sales by more than 400 percent and the fifth consecutive quarter of increased sales. "The increasing reality of online fraud and well-publicized data breaches underscores the need to definitively establish someone's online identity, an issue which has never been more challenging or important," said Steve Stuut, CEO of Jumio. "Making matters worse, traditional methods o
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom